Trial Profile
An Open-label, Single-dose Pilot Study to Evaluate the Efficacy and Safety of Varisolve® (Polidocanol Endovenous Microfoam) 0.125% [0.2%] for the Treatment of Symptomatic, Visible Varicose Veins With Saphenofemoral Junction (SFJ) Incompetence
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 May 2021
Price :
$35
*
At a glance
- Drugs Polidocanol (Primary)
- Indications Varicose veins
- Focus Therapeutic Use
- Sponsors BTG International
- 24 Sep 2014 New trial record